Information Provided By:
Fly News Breaks for February 26, 2016
ALKS
Feb 26, 2016 | 05:40 EDT
Barclays analyst Jonathan Eckard views Alkermes' 2016 guidance for Vivitrol as beatable and says ARISTADA uptake could be stronger than expected. The launch executions will likely be the focus this year with the negative ALKS 5461 depression data "behind the stock," Eckard tells investors in a post-earnings research note. He expects 2016 to highlight the value of the company's different parts and keeps an Overweight rating on Alkermes with a $50 price target.
News For ALKS From the Last 2 Days
There are no results for your query ALKS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.